{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:18:03Z","timestamp":1789190283212,"version":"build-2803163510"},"reference-count":38,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2024-0546_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Personalized reference intervals (prRI) have been proposed as a diagnostic tool for assessing measurands with high individuality. Here, we evaluate clinical performance of prRI using carcinoembryonic antigen (CEA) for cancer detection and compare it with that of reference change values (RCV) and other criteria recommended by clinical guidelines (e.g. 25\u202f% of change between consecutive CEA results (RV25) and the cut-off point of 5\u202f\u03bcg\/L (CP5)).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2024-0546_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clinical and analytical data from 2,638 patients collected over 19 years were retrospectively evaluated. A total 15,485 CEA results were studied. For each patient, we calculated prRI and RCV using computer algorithms based on the combination of different strategies to assess the number of CEA results needed, consideration of one or two limits of reference interval and the intraindividual biological variation estimate (CV<jats:sub>I<\/jats:sub>) used: (a)\u00a0publicly available (CV<jats:sub>I-EU<\/jats:sub>), (b) CV<jats:sub>I<\/jats:sub> calculated using an indirect method (CV<jats:sub>I-NOO<\/jats:sub>) and (c) within-person BV (CV<jats:sub>P<\/jats:sub>). For each new result identified falling outside the prRI, exceeding the RCV interval, RV25 or CP5, we searched for records identifying the presence of tumour at 3 and 12\u00a0months after the test. The sensitivity, specificity and predictive power of each strategy were calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2024-0546_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>PrRI approaches derived using CV<jats:sub>I-EU<\/jats:sub>, and both limits of reference interval achieve the best sensitivity (87.5\u202f%) and NPV (99.3\u202f%) at 3 and 12\u00a0months of all evaluated criteria. Only 3 results per patients are enough to calculate prRIs that reach this diagnostic performance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2024-0546_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PrRI approaches could be an effective tool to rule out new oncological findings during the active surveillance of patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2024-0546","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T09:41:05Z","timestamp":1722850865000},"page":"376-386","source":"Crossref","is-referenced-by-count":7,"title":["Clinical utility of personalized reference intervals for CEA in the early detection of oncologic disease"],"prefix":"10.1515","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5344-8402","authenticated-orcid":false,"given":"D\u00e9bora","family":"Mart\u00ednez-Espartosa","sequence":"first","affiliation":[{"name":"Biochemistry Department , Cl\u00ednica Universidad de Navarra , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00edbaliz","family":"Alegre","sequence":"additional","affiliation":[{"name":"Biochemistry Department , Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Navarra Institute for Health Research (IDISNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Casero-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Medida Tecnol\u00f3gica SL , M\u00e1laga , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-1505","authenticated-orcid":false,"given":"Jorge","family":"D\u00edaz-Garz\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Hospital Universitario La Paz , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Fern\u00e1ndez-Calle","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Hospital Universitario La Paz , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-2564","authenticated-orcid":false,"given":"Patricia","family":"Fuentes-Bullejos","sequence":"additional","affiliation":[{"name":"Biochemistry Department , Cl\u00ednica Universidad de Navarra , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Varo","sequence":"additional","affiliation":[{"name":"Biochemistry Department , Cl\u00ednica Universidad de Navarra , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Biochemistry Department , Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Navarra Institute for Health Research (IDISNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"2024123004263001553_j_cclm-2024-0546_ref_001","doi-asserted-by":"crossref","unstructured":"Hing, JX, Mok, CW, Tan, PT, Sudhakar, SS, Seah, CM, Lee, WP, et al.. Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance. Breast 2020;52:95\u2013101. https:\/\/doi.org\/10.1016\/j.breast.2020.05.005.","DOI":"10.1016\/j.breast.2020.05.005"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_002","doi-asserted-by":"crossref","unstructured":"Gaspar-Bl\u00e1zquez, JM, Pujol-Jaume, T, Pradera-Aug\u00e9, JM, Barco-S\u00e1nchez, A, Carbonell-Mu\u00f1oz, R, Filella-Pla, X, et al.. Recomendaciones para la optimizaci\u00f3n del uso de marcadores tumorales. Rev Lab Clin 2019;12:38\u201352. https:\/\/doi.org\/10.1016\/j.labcli.2018.09.002.","DOI":"10.1016\/j.labcli.2018.09.002"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_003","doi-asserted-by":"crossref","unstructured":"Molina, R, Barak, V, Van Dalen, A, Duffy, MJ, Einarsson, R, Gion, M, et al.. Tumor markers in breast cancer\u00a0\u2013 European group on tumor markers recommendations. Tumor Biol 2005;26:281\u201393. https:\/\/doi.org\/10.1159\/000089260.","DOI":"10.1159\/000089260"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_004","doi-asserted-by":"crossref","unstructured":"Wells, SA, Asa, SL, Dralle, H, Elisei, R, Evans, DB, Gagel, RF, et al.. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25:567\u2013610. https:\/\/doi.org\/10.1089\/thy.2014.0335.","DOI":"10.1089\/thy.2014.0335"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_005","doi-asserted-by":"crossref","unstructured":"Tuxen, MK, S\u00f6l\u00e9tormos, G, Dombernowsky, P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995;21:215\u201345. https:\/\/doi.org\/10.1016\/0305-7372(95)90002-0.","DOI":"10.1016\/0305-7372(95)90002-0"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_006","doi-asserted-by":"crossref","unstructured":"Duffy, MJ, Van Dalen, A, Haglund, C, Hansson, L, Klapdor, R, Lamerz, R, et al.. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718\u201327. https:\/\/doi.org\/10.1016\/s0959-8049(02)00811-0.","DOI":"10.1016\/S0959-8049(02)00811-0"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_007","doi-asserted-by":"crossref","unstructured":"Locker, GY, Hamilton, S, Harris, J, Jessup, JM, Kemeny, N, Macdonald, JS, et al.. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313\u201327. https:\/\/doi.org\/10.1200\/jco.2006.08.2644.","DOI":"10.1200\/JCO.2006.08.2644"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_008","doi-asserted-by":"crossref","unstructured":"Lin, YH, Wu, CH, Fu, HC, Chen, YJ, Chen, YY, Ou, YC, et al.. Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer. Cancer Biomarkers 2020;28:285\u201392. https:\/\/doi.org\/10.3233\/cbm-201455.","DOI":"10.3233\/CBM-201455"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_009","doi-asserted-by":"crossref","unstructured":"Grunnet, M, Sorensen, JB. Lung Cancer Carcinoembryonic antigen ( CEA ) as tumor marker in lung cancer. Lung Cancer 2012;76:138\u201343. https:\/\/doi.org\/10.1016\/j.lungcan.2011.11.012.","DOI":"10.1016\/j.lungcan.2011.11.012"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_010","doi-asserted-by":"crossref","unstructured":"Bozkurt-Yavuz, H, Akif-Bildirici, M, Yaman, H, Caner-Karahan, S, Aliyaz\u0131c\u0131o\u011flu, Y, \u00d6rem, A. Reference change value and measurement uncertainty in the evaluation of tumor markers. Scand J Clin Lab Invest 2021;81:601\u20135. https:\/\/doi.org\/10.1080\/00365513.2021.1979244.","DOI":"10.1080\/00365513.2021.1979244"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_011","doi-asserted-by":"crossref","unstructured":"Cartei, G, Cartei, F, Bertin, M, Padoan, A, Zustovich, F, Ornella Nicoletto, M, et al.. CA125 reference values change in male and postmenopausal female subjects. Clin Chem Lab Med 2013;51:413\u20139. https:\/\/doi.org\/10.1515\/cclm-2012-0414.","DOI":"10.1515\/cclm-2012-0414"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_012","doi-asserted-by":"crossref","unstructured":"Trap\u00e9, J, Botargues, JM, Porta, F, Ric\u00f3s, C, Badal, JM, Salinas, R, et al.. Reference change value for alpha-fetoprotein and its application in early detection of hepatocellular carcinoma in patients with hepatic disease. Clin Chem 2003;49:1209\u201311. https:\/\/doi.org\/10.1373\/49.7.1209.","DOI":"10.1373\/49.7.1209"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_013","doi-asserted-by":"crossref","unstructured":"Van Rossum, HH, Meng, QH, Ramanathan, LV, Holdenrieder, S. A word of caution on using tumor biomarker reference change values to guide medical decisions and the need for alternatives. Clin Chem Lab Med 2022;60:553\u20135. https:\/\/doi.org\/10.1515\/cclm-2021-0933.","DOI":"10.1515\/cclm-2021-0933"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_014","doi-asserted-by":"crossref","unstructured":"Lund, F, Petersen, PH, Fraser, CG. A dynamic reference change value model applied to ongoing assessment of the steady state of a biomarker using more than two serial results. Ann Clin Biochem 2019;56:283\u201394. https:\/\/doi.org\/10.1177\/0004563219826168.","DOI":"10.1177\/0004563219826168"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_015","doi-asserted-by":"crossref","unstructured":"Lund, F, Petersen, PH, Fraser, CG, S\u00f6l\u00e9tormos, G. Calculation of limits for significant bidirectional changes in two or more serial results of a biomarker based on a computer simulation model. Ann Clin Biochem 2015;52:434\u201340. https:\/\/doi.org\/10.1177\/0004563214555163.","DOI":"10.1177\/0004563214555163"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_016","doi-asserted-by":"crossref","unstructured":"Lund, F, Petersen, PH, Fraser, CG, S\u00f6l\u00e9tormos, G. Calculation of limits for significant unidirectional changes in two or more serial results of a biomarker based on a computer simulation model. Ann Clin Biochem 2015;52:237\u201344. https:\/\/doi.org\/10.1177\/0004563214534636.","DOI":"10.1177\/0004563214534636"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_017","doi-asserted-by":"crossref","unstructured":"Lund, F, Petersen, PH, Fraser, CG, S\u00f6l\u00e9tormos, G. Different percentages of false-positive results obtained using five methods for the calculation of reference change values based on simulated normal and ln-normal distributions of data. Ann Clin Biochem 2016;53:692\u20138. https:\/\/doi.org\/10.1177\/0004563216643729.","DOI":"10.1177\/0004563216643729"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_018","doi-asserted-by":"crossref","unstructured":"Co\u015fkun, A, Sandberg, S, Unsal, I, Cavusoglu, C, Serteser, M, Kilercik, M, et al.. Personalized reference intervals in laboratory medicine: a new model based on within-subject biological variation. Clin Chem 2021;67:374\u201384. https:\/\/doi.org\/10.1093\/clinchem\/hvaa233.","DOI":"10.1093\/clinchem\/hvaa233"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_019","doi-asserted-by":"crossref","unstructured":"Coskun, A, Sandberg, S, Unsal, I, Yavuz, FG, Cavusoglu, C, Serteser, M, et al.. Personalized reference intervals - statistical approaches and considerations. Clin Chem Lab Med 2022;60:629\u201335. https:\/\/doi.org\/10.1515\/cclm-2021-1066.","DOI":"10.1515\/cclm-2021-1066"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_020","doi-asserted-by":"crossref","unstructured":"Coskun, A, Sandberg, S, Unsal, I, Serteser, M, Aarsand, AK. Personalized reference intervals: from theory to practice. Crit Rev Clin Lab Sci 2022;59:501\u201316. https:\/\/doi.org\/10.1080\/10408363.2022.2070905.","DOI":"10.1080\/10408363.2022.2070905"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_021","doi-asserted-by":"crossref","unstructured":"Carobene, A, Banfi, G, Locatelli, M, Vidali, M. Personalized reference intervals: from the statistical significance to the clinical usefulness. Clin Chim Acta 2022;524:203\u20134. https:\/\/doi.org\/10.1016\/j.cca.2021.10.036.","DOI":"10.1016\/j.cca.2021.10.036"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_022","doi-asserted-by":"crossref","unstructured":"Tuxen, MK, S\u00f6l\u00e9tormos, G, Petersen, PH, Schi\u00f8ler, V, Dombernowsky, P. Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol 1999;74:12\u201322. https:\/\/doi.org\/10.1006\/gyno.1999.5414.","DOI":"10.1006\/gyno.1999.5414"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_023","doi-asserted-by":"crossref","unstructured":"Co\u015fkun, A, Aarsand, AK, Sandberg, S, Guerra, E, Locatelli, M, D\u00edaz-Garz\u00f3n, J, et al.. Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study. Clin Chem Lab Med 2022;60:543\u201352. https:\/\/doi.org\/10.1515\/cclm-2021-0283.","DOI":"10.1515\/cclm-2021-0283"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_024","doi-asserted-by":"crossref","unstructured":"Erden, G, Barazi, AO, Tezcan, G, Yildirimkaya, MM. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals. Scand J Clin Lab Invest 2008;68:212\u20138. https:\/\/doi.org\/10.1080\/00365510701601699.","DOI":"10.1080\/00365510701601699"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_025","doi-asserted-by":"crossref","unstructured":"Coskun, A, Sandberg, S, Unsal, I, Cavusoglu, C, Serteser, M, Kilercik, M, et al.. Personalized reference intervals: using estimates of within-subject or within-person biological variation requires different statistical approaches. Clin Chim Acta 2022;524:201\u20132. https:\/\/doi.org\/10.1016\/j.cca.2021.10.034.","DOI":"10.1016\/j.cca.2021.10.034"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_026","doi-asserted-by":"crossref","unstructured":"Wang, S, Zhao, M, Su, Z, Mu, R. Annual biological variation and personalized reference intervals of clinical chemistry and hematology analytes. Clin Chem Lab Med 2022;60:606\u201317. https:\/\/doi.org\/10.1515\/cclm-2021-0479.","DOI":"10.1515\/cclm-2021-0479"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_027","doi-asserted-by":"crossref","unstructured":"Carobene, A, Banfi, G, Locatelli, M, Vidali, M. Within-person biological variation estimates from the European Biological Variation Study (EuBIVAS) for serum potassium and creatinine used to obtain personalized reference intervals. Clin Chim Acta 2021;523:205\u20137. https:\/\/doi.org\/10.1016\/j.cca.2021.09.018.","DOI":"10.1016\/j.cca.2021.09.018"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_028","doi-asserted-by":"crossref","unstructured":"Co\u015fkun, A, Sandberg, S, Unsal, I, Cavusoglu, C, Serteser, M, Kilercik, M, et al.. Personalized and population-based reference intervals for 48 common clinical chemistry and hematology measurands: a comparative study. Clin Chem 2023;69:1009\u201330. https:\/\/doi.org\/10.1093\/clinchem\/hvad113.","DOI":"10.1093\/clinchem\/hvad113"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_029","unstructured":"Aarsand, A, Fernandez-Calle, P, Webster, C, Coskun, A, Gonzales-Lao, E, Diaz-Garzon, J, et al.. The EFLM biological variation database [Internet]. Available from: https:\/\/biologicalvariation.eu\/ [Accessed 26 Apr 2024]."},{"key":"2024123004263001553_j_cclm-2024-0546_ref_030","doi-asserted-by":"crossref","unstructured":"Marqu\u00e9s-Garc\u00eda, F, Nieto-Librero, A, Gonz\u00e1lez-Garc\u00eda, N, Galindo-Villard\u00f3n, P, Mart\u00ednez-S\u00e1nchez, LM, Tejedor-Gandux\u00e9, X, et al.. Within-subject biological variation estimates using an indirect data mining strategy. Spanish multicenter pilot study (BiVaBiDa). Clin Chem Lab Med 2022;60:1804\u201312. https:\/\/doi.org\/10.1515\/cclm-2021-0863.","DOI":"10.1515\/cclm-2021-0863"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_031","doi-asserted-by":"crossref","unstructured":"Coskun, A, Lippi, G. Personalized laboratory medicine in the digital health era: recent developments and future challenges. Clin Chem Lab Med 2023;62:402\u20139. https:\/\/doi.org\/10.1515\/cclm-2023-0808.","DOI":"10.1515\/cclm-2023-0808"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_032","doi-asserted-by":"crossref","unstructured":"Fokkema, M, Herrmann, Z, Muskiet, FAJ, Moecks, J. Reference change values for brain natriuretic peptides revisited. Clin Chem 2006;52:1602\u20133. https:\/\/doi.org\/10.1373\/clinchem.2006.069369.","DOI":"10.1373\/clinchem.2006.069369"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_033","doi-asserted-by":"crossref","unstructured":"Virtanen, P, Gommers, R, Oliphant, TE, Haberland, M, Reddy, T, Cournapeau, D, et al.. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods 2020;17:261\u201372. https:\/\/doi.org\/10.1038\/s41592-019-0686-2.","DOI":"10.1038\/s41592-020-0772-5"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_034","doi-asserted-by":"crossref","unstructured":"Harris, CR, Millman, KJ, van der Walt, SJ, Gommers, R, Virtanen, P, Cournapeau, D, et al.. Array programming with NumPy. Nature 2020;585:357\u201362. https:\/\/doi.org\/10.1038\/s41586-020-2649-2.","DOI":"10.1038\/s41586-020-2649-2"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_035","unstructured":"Python Software Foundation. Python language reference. [Internet]. versi\u00f3n 3. Available from: http:\/\/www.python.org."},{"key":"2024123004263001553_j_cclm-2024-0546_ref_036","doi-asserted-by":"crossref","unstructured":"McKinney, W. Data structures for statistical computing in Python. In: Proceedings of the 9th Python in Science Conference. Austin; 2010:51\u20136 pp.","DOI":"10.25080\/Majora-92bf1922-00a"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_037","doi-asserted-by":"crossref","unstructured":"Loh, TP, Ranieri, E, Metz, MP. Derivation of pediatric within-individual biological variation by indirect sampling method. Am J Clin Pathol 2014;142:657\u201363. https:\/\/doi.org\/10.1309\/ajcphzlqaeyh94hi.","DOI":"10.1309\/AJCPHZLQAEYH94HI"},{"key":"2024123004263001553_j_cclm-2024-0546_ref_038","doi-asserted-by":"crossref","unstructured":"Dallas-Jones, GR. Estimates of within-subject biological variation derived from pathology databases: an approach to allow assessment of the effects of age, sex, time between sample collections, and analyte concentration on reference change values. Clin Chem 2019;65:579\u201388. https:\/\/doi.org\/10.1373\/clinchem.2018.290841.","DOI":"10.1373\/clinchem.2018.290841"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2024-0546\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2024-0546\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T04:29:12Z","timestamp":1735532952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2024-0546\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8,28]]},"published-print":{"date-parts":[[2025,1,29]]}},"alternative-id":["10.1515\/cclm-2024-0546"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2024-0546","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]}}}